maia biotechnology, inc. is a targeted therapy, immune-oncology company, focused on development of first-in-class drugs with novel mechanisms of action that are intended to meaningfully improve and extend the lives of people with cancer. a privately-held company based in chicago, maia is led by a passionate, principled and highly experienced management team with significant drug development experience, committed to advancing promising agents into trials in humans clinical trials. maia’s business strategy is designed to advance a strong value proposition for its portfolio of potentially novel compounds. maia controls risk and enhances its opportunity for success by diversifying and generating this portfolio of assets with a variety of compounds with novel mechanisms of action which have potential activity in multiple tumor types. maia’s business model involves placing drug candidates in their own dedicated, r&d focused subsidiary company, which is supported by the common infrastru
Company profile
Ticker
MAIA
Exchange
Employees
Incorporated
Location
Fiscal year end
Industry (SIC)
SEC CIK
Corporate docs
Subsidiaries
MAIA Biotechnology Australia Pty Ltd. ...
MAIA stock data
Latest filings (excl ownership)
8-K
MAIA Biotechnology Announces $1.00 Million Private Placement
23 Apr 24
S-8
Registration of securities for employees
19 Apr 24
DEF 14A
Definitive proxy
16 Apr 24
8-K
Departure of Directors or Certain Officers
2 Apr 24
8-K
MAIA Biotechnology Announces $1.33 Million Private Placement
26 Mar 24
8-K
Other Events
25 Mar 24
424B5
Prospectus supplement for primary offering
25 Mar 24
10-K
2023 FY
Annual report
21 Mar 24
D
$5.70 mm in equity / options / securities to be acquired, sold $2.92 mm, 19 investors
21 Mar 24
8-K
Entry into a Material Definitive Agreement
13 Mar 24
Financial summary
Quarter (USD) | Sep 23 | Jun 23 | Mar 23 | Dec 22 | |
---|---|---|---|---|---|
Revenue | |||||
Cost of revenue | |||||
Operating income | |||||
Operating margin | |||||
Net income | |||||
Net profit margin | |||||
Cash on hand | |||||
Change in cash | |||||
Diluted EPS |
Annual (USD) | Dec 22 | |
---|---|---|
Revenue | ||
Cost of revenue | ||
Operating income | ||
Operating margin | ||
Net income | ||
Net profit margin | ||
Cash on hand | ||
Change in cash | ||
Diluted EPS |
Cash burn rate (est.) | Burn method: Change in cash | Burn method: Operating income | Burn method: FCF (opex + capex) | Last Q | Avg 4Q | Last Q | Avg 4Q | Last Q | Avg 4Q |
---|---|---|---|---|---|---|
Cash on hand (at last report) | 6.10 mm | 6.10 mm | 6.10 mm | 6.10 mm | 6.10 mm | 6.10 mm |
Cash burn (monthly) | 1.01 mm | 663.25 k | 1.65 mm | 1.50 mm | 1.63 mm | 1.41 mm |
Cash used (since last report) | 7.04 mm | 4.61 mm | 11.47 mm | 10.42 mm | 11.29 mm | 9.78 mm |
Cash remaining | -935.47 k | 1.50 mm | -5.37 mm | -4.31 mm | -5.18 mm | -3.68 mm |
Runway (months of cash) | -0.9 | 2.3 | -3.2 | -2.9 | -3.2 | -2.6 |
Institutional ownership, Q2 2023
4.4% owned by funds/institutions
13F holders | Current |
---|---|
Total holders | 11 |
Opened positions | 7 |
Closed positions | 3 |
Increased positions | 2 |
Reduced positions | 1 |
13F shares | Current |
---|---|
Total value | 547.65 mm |
Total shares | 905.74 k |
Total puts | 0.00 |
Total calls | 0.00 |
Total put/call ratio | – |
Largest owners | Shares | Value |
---|---|---|
Stan Smith | 648.29 k | $5.06 mm |
Vanguard | 93.50 k | $205.70 mm |
Lynwood Capital Management | 35.00 k | $77.00 mm |
Geode Capital Management | 33.99 k | $74.77 mm |
Bridgeway Capital Management | 26.60 k | $58.52 mm |
Citadel Advisors | 23.39 k | $51.45 mm |
Naviter Wealth | 22.17 k | $48.77 mm |
Renaissance Technologies | 10.80 k | $24.00 k |
BLK Blackrock | 8.02 k | $17.64 mm |
Tower Research Capital | 3.96 k | $8.72 mm |
Recent insider trades
Date | Owner | Security | Transaction | Code | Indirect | 10b5-1 | $Price | #Shares | $Value | #Remaining |
---|---|---|---|---|---|---|---|---|---|---|
25 Apr 24 | Ngar Yee Louie | Common Stock | Buy | Acquire P | No | No | 2.03 | 19,665 | 39.92 k | 1,167,189 |
25 Apr 24 | Ngar Yee Louie | Warrants Common Stock | Buy | Acquire P | No | No | 2.26 | 19,665 | 44.44 k | 19,665 |
25 Apr 24 | Stan Smith | Common Stock | Buy | Acquire P | Yes | No | 2.03 | 147,492 | 299.41 k | 1,005,060 |
25 Apr 24 | Stan Smith | Warrants Common Stock | Buy | Acquire P | Yes | No | 2.26 | 147,492 | 333.33 k | 147,492 |
31 Mar 24 | Jean-Manasse Theagene | Stock Options Common Stock | Grant | Acquire A | No | No | 2.2 | 9,193 | 20.22 k | 9,193 |
31 Mar 24 | Cristian Luput | Stock Options Common Stock | Grant | Acquire A | No | No | 2.2 | 9,193 | 20.22 k | 9,193 |
31 Mar 24 | Ramiro Guerrero | Stock Options Common Stock | Grant | Acquire A | No | No | 2.2 | 9,193 | 20.22 k | 9,193 |
News
MAIA Biotechnology Announces 170,940 Share Purchase By Director Adelina Louie In Private Placement
26 Mar 24
MAIA Biotechnology Announces $1.33M Private Placement of 0.6M Shares at $2.295/Share
26 Mar 24
MAIA Biotechnology Announces 170,940 Share Purchase By Director Stan Smith, PhD In A $2.9M Private Placement
22 Mar 24
MAIA Biotechnology Announces Efficacy Of THIO; Combination THIO 180mg + Cemiplimab Achieved 38% Overall Response Rate In Difficult-To-Treat, Third-Line Non-Small Cell Lung Cancer
6 Mar 24
MAIA Biotechnology CEO Details Immuno-Oncology Cancer Treatment Candidates And Development Pipeline In Letter To Shareholders
5 Mar 24
Press releases
MAIA Biotechnology to Present at Two Investor Conferences in April 2024
5 Apr 24
MAIA Biotechnology Announces Share Purchases by Directors Cristian Luput and Ramiro Guerrero
28 Mar 24
MAIA Biotechnology Announces Share Purchase by Director Adelina Louie in Private Placement
26 Mar 24
MAIA Biotechnology Announces $1.33 Million Private Placement
26 Mar 24
MAIA Biotechnology Announces Share Purchase by Director Stan Smith, PhD in a $2.9 Million Private Placement
22 Mar 24